The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
GLP-1 analogs are used as agents in the existing treatment of obesity. However, there are lack of previous reports on the effectiveness and role of GLP-1 analogs in the development of obesity traits in patients with functionally impaired hypothalamus. With this preliminary study, the investigators would explore the role of GLP-1 analogues to identify eating behavioral pathology subtype differences in the therapeutic efficacy of GLP-1 analogues in hypothalamic obesity patients. This will allow us to identify the role of specific nuclei which could be the pathogenesis of hypothalamic obesity. Our hypotheses: GLP-1 analogs will effectively induce weight loss in patients with hypothalamic obesity, and different subtypes of hypothalamic obesity will respond differently to GLP-1 analogs.
• Patients diagnosed with a hypothalamic tumor and treated surgically with confirmed hypothalamic damage
• 19 years of age or older
• Have a body mass index of at least 27 and less than 30 (27≤BMI\<30) and one or more confirmed weight-related medical conditions, or a body mass index of 30 or greater (BMI≥30).
• Voluntarily agreed to participate in the study after receiving a full explanation of the study.